MD Anderson scientists have pinpointed how melanoma tumors resist the cancer drug ipilimumab: genetic mutations in an immune pathway.

Shares in tiny Galectin Therapeutics fell 50% in after-hours trading on the back of data from a Phase IIa nonalcoholic steatohepatitis trial.

GlaxoSmithKline has found a buyer for a French drug discovery site rendered redundant by its revamped dual-hub R&D model.

Immunic has raised €17.5 million from LSP and LifeCare Partners in Series A round and bought cytokine inhibitor and Crohn’s disease programs from 4SC.

Shire has returned rights to the two biosimilars that Baxalta had in development.

Galapagos CEO Onno van de Stolpe has confirmed that the standstill agreement stopping Gilead from increasing its stake in his company is still active.

The Cambridge, MA-based company is ready to graduate from a venture-oriented CEO to a former pharma exec ready to jump into the clinical fray.

BMS has partnered with Nektar Therapeutics in a clinical collaboration that aims to boost the efficacy of Opdivo with Nektar candidate NKTR-214.

Startup Fortis has emerged from stealth mode with an $18 million Series A financing led by Avalon Ventures.